6 of the best: how China’s new biotech vanguard is banking billions from breakthroughs



The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants after a three-year slump – may have surprised casual observers.

But according to Helen Chen, one of the most respected analysts and advisers in China’s life sciences space, the supercharged sector’s real renaissance came two years earlier.

In December 2022, US drug maker MSD agreed to license global (excluding China) rights to develop and commercialise seven preclinical antibody-drug conjugate (ADC) cancer candidates from Sichuan Kelun-Biotech Biopharmaceutical, paying US$175 million upfront and up to US$9.3 billion in milestone payments.

“The Kelun – MSD deal was a significant milestone,” said Chen, who heads the Shanghai-based biopharmaceutical and life sciences practice L.E.K. Consulting. “There was a leap of faith for MSD to take a chance on Kelun – and for Kelun to make the investments.”

ADCs – “guided-missile” therapies that deliver chemotherapy directly to cancer cells with fewer side effects – are among the fastest growing areas of biotech.

Eight months later, private-equity-backed Aiolos licensed global rights for an asthma treatment from Jiangsu Hengrui Pharmaceuticals for an undisclosed sum.

  • Related Posts

    How tiny capacitors became the latest AI-driven investor darling

    Demand for multilayer ceramic capacitors (MLCCs), tiny electronic components found in everything from smartphones to electric vehicles, is surging as the artificial intelligence boom triggers new production. MLCCs, which act…

    Continue reading
    Nio slams EV price wars in China as costs surge, defying cuts by rival Li Auto

    Chinese electric vehicle maker Nio has staked out a contrasting position on pricing to its domestic rival, Li Auto, with a top executive suggesting that carmakers must prioritise profitability as…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *